EUVIMEDEUVIMED entdecken
Crossref

Quality and safety considerations for traditional kratom and commercial products labelled as kratom

P N Brown, M Chan

Planta Medica · 01.03.2026 · 92 (03) · 214

DOI: 10.1055/s-0045-1814902 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von P N Brown und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kratom is the common name attributed to Mitragyna speciosa Korth., a deciduous tree of the Rubiaceae family native to Southeast Asia. Historically kratom leaves were chewed or consumed as a tea to mitigate fatigue and alleviate pain, particularly among manual laborers [ 1 ]. The alkaloids are recognized as the primary active compounds representing 0.5-3% of the total dry weight, with mitragynine reported to comprise of 51-82% of the alkaloid composition [ 2 ] [ 3 ]. Other pharmacologically active alkaloids found in leaf include paynantheine, speciogynine, speciociliatine, and mitraciliatine [ 1 ] [ 3 ]. With growing demand over the last decade, kratom leaves are primarly harvested from cultivated trees which has had an impact on the alkaloid distrbution and consequently the safety profile [ 3 ]. Another alkaloid, initially thought to be present in native kratom leaf, 7-hydroxymitragynine (7-OH) is now recognized as a human metabolite of mitragynine and a post-harvest oxidative by-product found in trace levels ranging from 0.03-0.40 mg/g dry leaf [ 2 ] [ 3 ] [ 4 ]. Recently, there have been a plethora of products comprised of predominately 7-OH flooding the market, many of which are erroneously labelled as “kratom extracts”. Given that 7-OH is 3-22 times more potent than morphine at opioid receptors and demonstrates abuse liability, these products pose a public health risk [ 2 ] [ 5 ]. This study aimed to evaluate the phytochemical implications of the changing supply chain from wild-crafted to cultiavted leaf and review commerical products readily available in the U.S. market in consideration of regulatory and safety implications for public health. Disclosures : PB serves as a scientific expert and regulatory consultant on botanical dietary ingredients, including kratom. No clients had any contribution or input into this study. MC has nothing to disclose. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Brown, P. N., & Chan, M. (2026). Quality and safety considerations for traditional kratom and commercial products labelled as kratom. Planta Medica, 92(03), 214. https://doi.org/10.1055/s-0045-1814902

Vancouver

Brown PN, Chan M. Quality and safety considerations for traditional kratom and commercial products labelled as kratom. Planta Medica. 2026;92(03):214. doi:10.1055/s-0045-1814902

BibTeX
@article{Brown2026,
  author = {Brown, P N and Chan, M},
  title = {Quality and safety considerations for traditional kratom and commercial products labelled as kratom},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {214},
  doi = {10.1055/s-0045-1814902}
}
Kostenlos starten →